The primary therapeutic purpose of Fertipig HCG is applied across domains where additional symptomatic support is needed for symptoms related to systemic imbalance in the reproductive health of female pigs.

This medication is commonly used to help manage the clinical condition known as anoestrus—the absence of the expected heat cycle—which includes addressing post-weaning anoestrus in sows, and is commonly used to help with managing the induction of oestrus in gilts, and managing cases of seasonal anoestrus (or summer infertility). The core benefit is helping address symptom clusters that may become intense or disruptive, which supports general well-being during symptomatic phases of reproductive management.

“This preparation is relevant for easing symptom clusters that may become intense or disruptive, offering supportive relief in situations requiring temporary assistance in cycle stabilization.”

Managing Reproductive Cycle Failure and Anoestrus

Fertipig HCG may be applied to help manage the return to a fertile cycle in weaned sows that fail to return to oestrus within the expected interval, and it may assist with managing the induction of oestrus in gilts. This medication is relevant in clinical settings that involve reproductive synchronization protocols. Through its supportive role, it assists with maintaining functional stability in the reproductive cycle and provides support that helps ease the overall symptom burden on the system.

Regulatory References

1. UK Veterinary Medicines Directorate Summary of Product Characteristics

Target Populations and Prohibitions

Fertipig HCG is a specialized veterinary medicine whose use is strictly defined by regulatory guidelines. The product is intended exclusively for its target species: Pigs, specifically Sows after weaning and Gilts for the induction of oestrus.

Use of the medicine is formally contraindicated in several animal populations and physiological states:

Furthermore, the label mandates conditional use restrictions. Administration is cautioned against during the primary luteinised phase or middle of the cycle, as this may increase the risk of ovarian cysts. The product label also specifies crucial safety precautions for the handler: Pregnant women or women whose pregnancy status is unknown must not handle or administer the medicine, and individuals with a known hypersensitivity to gonadotrophins must avoid all contact.

The section on interactions for Fertipig HCG, a specialized gonadotropin preparation, provides clear, regulatory-aligned information to define its use in conjunction with other substances.

Documented Interaction Status

The official regulatory prescribing information formally states that there are no specific drug-drug interactions known for Fertipig HCG. This means that formal chemical, metabolic, or pharmacokinetic interactions—such as those involving enzyme systems, drug transporters, or pharmacodynamic additive effects that would alter drug exposure (AUC/Cmax)—are not documented in the official regulatory information. Consequently, no specific contraindications based on exposure modification are listed. Interactions with food, alcohol, or herbal products are also not specified in the labeling.

Mandatory Separation Rule

The core constraint listed in the product's official information is one of pharmaceutical incompatibility. This is a procedural restriction that mandates how the medicine must be handled before administration. To maintain solution integrity and prevent physical reactions, Fertipig HCG must not be mixed with any other veterinary medicinal products in the same syringe or vial. This mandatory separation is required in the absence of compatibility studies and is the primary interaction-related requirement.

Fertipig HCG's mechanism of action is mediated by its active component, Human Chorionic Gonadotropin (HCG), a glycoprotein hormone structurally analogous to Luteinizing Hormone (LH). HCG selectively targets and acts as an agonist for the LH/choriogonadotropin receptor (LHCG-R), a G-protein-coupled receptor primarily expressed on ovarian and testicular cells. Receptor binding initiates the G alphas signaling cascade, leading to the activation of adenylyl cyclase and a subsequent intracellular increase in cyclic adenosine monophosphate (cAMP) concentrations. This cAMP surge activates Protein Kinase A (PKA), which then phosphorylates various target proteins to modulate gene transcription and steroidogenesis. In the ovary, HCG specifically promotes the final maturation of the dominant follicle, induces ovulation, and facilitates the post-ovulatory transformation of the granulosa and theca cells into the corpus luteum, thereby stimulating the synthesis and secretion of progesterone. These actions result in a system-level modulation of the estrous cycle, mimicking the natural pre-ovulatory LH surge.

The use of Fertipig HCG is dictated by standardized, fixed protocols. This medicine is administered via the parenteral route, exclusively as an intramuscular (I.M.) injection. This method ensures the active agents are delivered consistently according to the predefined time-relationship constraints of the reproductive cycle management program.

Official Dosing and Frequency

The administration follows a single-shot regimen and is not intended for cyclic or maintenance use over time. The dose is fixed and non-adjustable: one administration contains a specific concentration of 400 IU Equine Serum Gonadotrophin and 200 IU Chorionic Gonadotrophin, delivered in 5 ml of the final solution. Standard instructions explicitly state that the dose must not be modified for any reason, as increasing the quantity does not result in greater efficacy. For sows, the precise timing of administration is critical, requiring the single dose to be given within 24 hours after weaning.

Preparation and Administration Constraints

Due to its composition, the product is supplied as a two-part system—a lyophilisate and a solvent—which mandates reconstitution to prepare the homogenous solution for injection. This preparation is a required step before use. There are two critical administration constraints to ensure proper delivery: the final solution must not be mixed with any other veterinary medicinal products in the syringe, and the injection technique must specifically avoid deposition into the subcutaneous fat. These requirements define the procedural steps for correct application.

Research Evidence / Overview of Studies for Fertipig HCG

Research Evidence for Managing Anoestrus in Weaned Sows

Research exploring the use of this combination product in sows studied for the absence of expected post-weaning oestrus has been conducted primarily through controlled on-farm trials and observational studies. These studies have monitored adult female pigs and examined outcomes related to systemic or functional imbalance. The main measurements monitored included the Weaning-to-Oestrus Interval (WEOI) and outcomes tracked in the subsequent reproductive cycle, such as farrowing rate and litter size.

Studies report how symptoms evolved in the observed populations. Some studies reported measurements where the WEOI was observed to be shorter compared to untreated animals. What remains uncertain is the consistency of the evidence regarding long-term outcomes. Research reports describe patterns where subsequent productivity measures have shown considerable variability across different published studies.

Research Evidence for Oestrus Induction in Gilts

The evidence base for managing the onset of the reproductive cycle in gilts is largely established by Randomized Controlled Trials (RCTs). These studies focused on prepubertal gilts and explored the effect on the timing and percentage of animals that entered the first heat cycle, tracking outcomes related to physiological strain.

Research findings describe patterns where a higher proportion of gilts reached the oestrus phase when compared to controls in the studies. Research monitored patterns related to a shorter time interval until the onset of oestrus. Although research provides insight into short-term changes, evidence is limited detailing the influence of the gilts’ initial physiological status on the final observed outcome.

Long-Term Outcomes and Follow-Up in Research

The studies conducted for regulatory review examined outcomes over defined time intervals. Follow-up durations were limited, often focusing on the oestrus detection interval and tracking the Reproductive Cycle Completion.

Research provides context regarding subsequent outcomes, but research exploring the sustainability of the observed pattern across multiple reproductive cycles beyond the first treated cycle is not well established. Comparative evidence is lacking regarding the long-term health trajectory of treated animals versus untreated controls.

Key Studies & References

1. Summary of Product Characteristics (SPC) for Fertipig HCG

Common questions about Fertipig HCG (FAQ)

Q: What are the storage requirements for this medication?

Official product information states that the tablets should be stored at controlled room temperature, which should not exceed 30°C (86°F). It is also important to ensure the medication is kept safely out of the reach of children.

Q: Is it safe to drink alcohol while taking this medicine?

Regulatory documents do not list a direct interaction between this medicine and alcohol. However, official safety information indicates that concurrent alcohol use may potentially worsen central nervous system side effects like dizziness and headache. It may also increase the risk of liver problems.

Q: Does this medication make you sleepy or affect your ability to drive?

This medicine may cause certain central nervous system side effects, including dizziness and headache, according to the official product label. If these effects are experienced, regulatory information advises caution regarding activities such as driving and operating machinery.

Q: Is it safe to use this drug long-term?

Official warnings indicate that long-term use of this medicine is associated with a risk of irreversible retinal damage, a condition known as retinopathy. This risk is generally related to the total amount of medicine taken over time. For this reason, official guidance recommends regular eye examinations, typically at least once a year, during long-term treatment.

Q: What are the contraindications (when should I not take it)?

Official contraindication information advises against taking this medicine if there is a known allergy or hypersensitivity to drugs called 4-aminoquinoline compounds. It is also contraindicated if there are pre-existing retinal or visual field changes, regardless of the cause.

Q: Can this be taken with milk or food?

Official administration guidance suggests that the tablets should be taken by mouth with food or milk.

Q: Can a pregnant woman use this medication?

Official information indicates that the drug crosses the placenta. Data from clinical experience have not shown a significantly increased risk of major birth defects. Official documents state that use during pregnancy should only occur when the potential benefit is considered greater than the potential risk to the fetus.

How to Store and Dispose of Fertipig HCG?

Strict storage and disposal protocols are mandatory for this veterinary medicine, as defined in regulatory documentation to ensure product stability and environmental safety.

Official Storage Requirements

Both components must be kept in the original package. Once the solution for injection is prepared (reconstituted), it must be used immediately and the product cannot be stored for later use. For safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Fertipig HCG and its waste materials must be disposed of according to local regulatory requirements for veterinary medicinal products. It is explicitly forbidden to dispose of the product via household waste or by pouring it into the wastewater system.